A company called Applied Therapeutics was testing a medicine for people with diabetes who have heart problems. The test did not show that the medicine helped these patients, so the company's shares became less valuable and lost over 35% of their worth. Other stocks are also moving because of different reasons. Read from source...

1. The headline is misleading and sensationalized. It suggests that the only reason for the stock price drop is the disappointing trial results, while ignoring other possible factors such as market conditions, investor sentiment, or competitors' activities. A more accurate headline would be "Applied Therapeutics Shares Plummet After Disappointing Trial Results in Diabetic Cardiomyopathy Patients".
2. The article does not provide enough context or background information about the trial, the drug, or the disease. For example, it does not mention what Diabetic Cardiomyopathy is, how common it is, or what are the current treatments available. This makes it hard for readers to understand the significance and relevance of the trial results.
3. The article uses vague and ambiguous language to describe the trial results. For example, it says that the drug failed to achieve its primary endpoint of "stabilization or improvement in cardiac functional capacity". However, it does not specify by how much the drug failed to meet the criteria, or what was the p-value or statistical significance of the difference between the treatment and placebo groups. This makes it hard for readers to assess the credibility and reliability of the trial data.
4. The article relies heavily on quotes from company insiders and analysts, who may have conflicts of interest or biased opinions about the drug and the trial. For example, it cites a quote from the CEO of Applied Therapeutics, Dr. Kiran Machekumar, who says that the trial results are "disappointing" but that the company remains committed to advancing its pipeline of drugs for rare diseases. However, the article does not disclose whether Dr. Machekumar has any personal or financial stake in the success or failure of the drug, nor does it provide any counterarguments or alternative perspectives from other experts or stakeholders.
5. The article ends with a list of other stocks moving in Friday's mid-day session, which seems irrelevant and disconnected from the main topic of the article. It appears that the author is trying to fill space or attract attention by mentioning unrelated stocks, without providing any analysis or explanation of why they are moving. This makes it seem like the article is poorly researched or poorly organized.

Negative

Explanation: The article is reporting that Applied Therapeutics shares are trading lower by over 35% due to the disappointing results of their Phase 3 trial. This is clearly a negative sentiment for the company and its investors, as it indicates that their product candidate did not meet its primary endpoint and may face difficulties in obtaining regulatory approval or reaching the market. Additionally, the article mentions other stocks moving in Friday's mid-day session, which could be seen as neutral or positive news for those companies, but does not provide any specific details or reasons for their movement. Overall, the focus of the article is on the negative outcome for Applied Therapeutics and its impact on the company's stock price and future prospects.

AI can analyze the entire article and provide a comprehensive investment recommendation based on the current market conditions, company performance, and potential future growth opportunities. Additionally, AI can assess the risks associated with each stock and provide a risk score for each one.